Want to see SE:SANION full AI Analyst Report?
Top Page
Saniona AB
(SANION)
Select Model
Select Model
Rating:62Neutral
Price Target:
kr13.50
▼(-36.02% Downside)
Action:Reiterated
Date:05/27/26
Score is driven primarily by strong financial performance (high profitability, positive cash generation, and a debt-free balance sheet). This is tempered by weak technical momentum (below key moving averages with negative MACD) and limited valuation support due to a negative P/E and no dividend yield data.
Positive Factors
Debt-free balance sheet
A debt-free balance sheet gives durable financial flexibility: lowers bankruptcy and interest-rate risks, supports multi-year R&D and partnership funding, and enables opportunistic investments or licensing without immediate external financing needs, strengthening resilience.
Negative Factors
Revenue volatility
Sharp swings in revenue reduce predictability of cash flows and strain planning for multi-year drug development. Dependence on uneven milestone, licensing or timing-driven revenues can compress margins and force reactive financing or program delays during revenue troughs.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A debt-free balance sheet gives durable financial flexibility: lowers bankruptcy and interest-rate risks, supports multi-year R&D and partnership funding, and enables opportunistic investments or licensing without immediate external financing needs, strengthening resilience.
Read all positive factors
Saniona AB (SANION) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr1.79B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)8.1
Beta (1Y)0.01
Revenue Growth26.85%
EPS Growth-18.05%
CountrySE
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)1.59
Shares Outstanding138,030,140
10 Day Avg. Volume913,988
30 Day Avg. Volume1,064,614
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr11.00M
Saniona AB Business Overview & Revenue Model
Company Description
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system dis...
How the Company Makes Money
null...
Saniona AB Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 429.29M | 434.40M | 334.67M | 16.84M | 15.28M | 10.48M |
| Gross Profit | 303.85M | 286.37M | 329.58M | 11.78M | 10.81M | 5.85M |
| EBITDA | 241.74M | 281.45M | 251.90M | -68.28M | -198.41M | -398.86M |
| Net Income | 219.56M | 284.67M | 188.71M | -95.81M | -245.36M | -410.90M |
Balance Sheet | ||||||
| Total Assets | 651.46M | 679.74M | 339.73M | 64.14M | 153.70M | 440.25M |
| Cash, Cash Equivalents and Short-Term Investments | 531.98M | 580.82M | 303.26M | 30.96M | 111.71M | 356.86M |
| Total Debt | 0.00 | 0.00 | 10.50M | 71.41M | 81.52M | 99.77M |
| Total Liabilities | 53.19M | 44.58M | 107.92M | 86.08M | 100.99M | 158.25M |
| Stockholders Equity | 598.27M | 635.16M | 231.82M | -21.94M | 52.71M | 282.00M |
Cash Flow | ||||||
| Free Cash Flow | 177.29M | 200.30M | 249.07M | -85.66M | -282.52M | -346.52M |
| Operating Cash Flow | 252.20M | 273.86M | 249.20M | -85.53M | -281.54M | -345.04M |
| Investing Cash Flow | -82.15M | -77.62M | -124.00K | -129.00K | 6.84M | 43.16M |
| Financing Cash Flow | 109.59M | 108.19M | 23.25M | -7.97M | -20.52M | 50.60M |
Saniona AB Technical Analysis
Negative
21.10
Price Trends
13.78
Negative
16.44
Negative
16.78
Negative
Market Momentum
-0.32
Negative
45.62
Neutral
56.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SANION, the sentiment is Negative. The current price of 21.1 is above the 20-day moving average (MA) of 13.23, above the 50-day MA of 13.78, and above the 200-day MA of 16.78, indicating a bearish trend. The MACD of -0.32 indicates Negative momentum. The RSI at 45.62 is Neutral, neither overbought nor oversold. The STOCH value of 56.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SANION.
Saniona AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | kr533.52M | 3.34 | 81.19% | ― | ― | ― | |
62 Neutral | kr1.79B | 8.13 | 167.77% | ― | 26.85% | -18.05% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr220.48M | 0.90 | -16.90% | ― | -72.49% | ― | |
47 Neutral | kr638.02M | -1.72 | ― | ― | 109.22% | 27.30% | |
45 Neutral | kr823.42M | -8.60 | -58.41% | ― | ― | -12.27% | |
42 Neutral | kr715.04M | -3.58 | -35.03% | ― | ― | 46.92% |
* Healthcare Sector Average
SE:SANION
Saniona AB
12.93
2.63
25.53%
SE:ONCO
Oncopeptides AB
1.62
0.25
18.43%
SE:SYNACT
SynAct Pharma AB
18.40
-0.16
-0.86%
SE:XBRANE
Xbrane Biopharma AB
10.75
-20.40
-65.49%
SE:XSPRAY
Xspray Pharma AB
15.02
-30.02
-66.65%
SE:CANTA
Cantargia AB
2.17
0.76
54.20%
Saniona AB Corporate Events
Saniona launches virtual R&D Day to spotlight SAN2668 for severe pediatric epilepsies
Jun 4, 2026
Saniona will host a virtual RD Day on June 17, 2026, to showcase SAN2668, its novel treatment candidate targeting GABAA receptors for severe pediatric epilepsies such as developmental and epileptic encephalopathies. The event, featuring leading pe...
Saniona shareholders block pay report as board pulls capital and incentive proposals
May 27, 2026
Saniona AB’s annual shareholders’ meeting approved the 2025 financial statements and decided that no dividend will be paid, with available funds carried forward, while granting discharge from liability to the board and CEO. The meeting...
Saniona Deepens Losses but Bolsters Cash as Pipeline Nears Clinic
May 26, 2026
Saniona reported first-quarter 2026 revenue of SEK 4.6 million, down from SEK 9.8 million a year earlier, and a net loss of SEK 46.2 million as it increased investment in its pipeline. Cash and cash equivalents rose to SEK 532 million, providing a...
Saniona Schedules Q1 Investor Call Amid Advancing CNS Pipeline
May 20, 2026
Saniona has invited investors to a Q1 2026 call on 26 May, where management will present quarterly results and provide a broader company update, followed by an online QA session. The event, which will be accessible via webcast with replay availabi...
Saniona Publishes Comprehensive 2025 Annual Report Covering Operations, Financials and Governance
Apr 30, 2026
Saniona AB has published its 2025 annual report, providing a comprehensive overview of the year’s activities, including a CEO letter, pipeline update, scientific background, share performance, five-year summary, and risk factors. The report ...
Saniona convenes 2026 AGM with governance and long-term incentive plan on agenda
Apr 24, 2026
Saniona AB has called its annual shareholders’ meeting for 27 May 2026 in Malmö, setting out formal participation requirements including Euroclear Sweden registration by 19 May and advance notice by 21 May, as well as rules for proxy re...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.